Authors

Daniel J. George, MD

Latest:

Dr. George on the Importance of Understanding Mutations in Prostate Cancer

Daniel J. George, MD, discusses the importance of understanding mutations in prostate cancer.

Daniel J. George, MD, Duke

Daniel J. George, MD, Duke Cancer Center

Latest:

Advanced Clear Cell Renal Cell Carcinoma: Putting Advances Into Practice

Daniel J. George, MD, Duke University Medical Center

Daniel M. Geynisman, MD

Latest:

Dr. Geynisman on Patient Preferences for Treatment of RCC

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses patient preferences for the treatment of renal cell carcinoma (RCC).

Daniel Morgensztern, MD

Latest:

Dr. Morgensztern on Advances With Amivantamab in NSCLC

Daniel Morgensztern, MD, discusses ongoing research with amivantamab-vmjw in non–small cell lung cancer.

Daniel O'Connell, MD

Latest:

Dr. O'Connell on a Phase II Trial to Evaluate Optune in Grade III Brain Cancer

Daniel O'Connell, MD, University of California at Los Angeles, discusses a phase II trial testing the benefits of tumor treating fields with Optune for bevacizumab-naive patients with grade III malignant glioma.

Daniel P. Petrylak, MD

Latest:

Dr Petrylak on the Shifting Role of Avelumab Maintenance in Metastatic Urothelial Cancer

Daniel Petrylak, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the use of avelumab maintenance in urothelial cancer.

Daniel P. Petrylak, MD, Yale

Daniel P. Petrylak, MD, Yale School of Medicine

Daniel P. Petrylak, MD, Yale University Cancer Center

Daniel Petrylak, MD, Yale School of Medicine

Latest:

The Emerging Role of Chemotherapy in Metastatic Prostate Cancer

Daniel Petrylak, MD, Yale University

Daniel Pollyea, MD, MS, University of Colorado, Anschutz Medical Campus

Daniel R. Couriel, MD

Latest:

Dr. Couriel Discusses Treating GVHD With Photopheresis

Dr. Daniel Couriel, from the Unversity of Michigan Comprehensive Cancer Center, Discusses Treating GVHD With Photopheresis

Daniel R. Saltzstein, MD, Urology San Antonio

Daniel R. Vlock, MD

Latest:

Dr. Vlock on Anti—CD20 Interleukin-2 Immunocytokine in NHL

Daniel R. Vlock, MD, founder and CEO, Alopexx Pharmaceuticals, discusses a phase I/II study of an antiâ€“CD20 interleukin-2 immunocytokine in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

Daniel Sargent, PhD

Latest:

Daniel Sargent on International Collaboration for Colon Cancer Research

Daniel Sargent, PhD, professor of Oncology and Biostatistics, Mayo Clinic in Rochester, Minnesota, discusses the IDEA initiative, which is an international study to examine if patients with colon cancer would benefit from reducing the duration of adjuvant therapy from 3 months to 6 months to reduce side effects and cost.

Daniel V. Catenacci, MD, University of Chicago

Latest:

Global Updates in Advanced Gastric Cancer from ESMO 2020

Daniel Vaena, MD

Latest:

Dr. Vaena on Major Advances in Metastatic Prostate Cancer

Daniel Vaena, MD, hematologist/medical oncologist and hematologist, West Cancer Center, discusses progress made in the treatment of patients with metastatic prostate cancer.